Michael Adams, MD
Internal Medicine · Granite City, ILNPI 1851383301
Payments from drug & device makers
Across 273 payments — averaging $57.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Astrazeneca UK Limited$3K
- Novo Nordisk$996
- Pfizer$518
- AbbVie$253
- Abbott$201
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,507100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $8,774 |
| Astrazeneca UK Limited | 2 | $3,308 |
| Novo Nordisk | 80 | $996 |
| Pfizer | 57 | $518 |
| AbbVie | 14 | $253 |
| Abbott | 4 | $201 |
| Exact Sciences | 6 | $195 |
| Esperion Therapeutics, Inc. | 5 | $189 |
| Bayer | 2 | $149 |
| Lilly USA, LLC | 7 | $124 |
| Mallinckrodt Hospital Products Inc. | 1 | $96 |
| Teva Pharmaceuticals USA, Inc. | 1 | $86 |
| Amgen | 4 | $83 |
| Boehringer Ingelheim | 3 | $64 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| GSK | 3 | $48 |
| Bausch Health US, LLC | 2 | $47 |
| Johnson & Johnson | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Novartis | 2 | $36 |
| Lundbeck LLC | 2 | $32 |
| Merck | 2 | $31 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Viiv Healthcare Company | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Insulet Corporation | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,700 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 191 | $243,274 |
| FarxigaDapagliflozin Propanediol | 169 | $173,061 |
| EliquisApixaban | 108 | $117,063 |
| JanuviaSitagliptin Phosphate | 51 | $59,672 |
| JardianceEmpagliflozin | 42 | $55,689 |
| XareltoRivaroxaban | 41 | $50,659 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 77 | $50,456 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $47,158 |
| MounjaroTirzepatide | 39 | $44,285 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $35,521 |
| ProliaDenosumab | 20 | $35,178 |
| LinzessLinaclotide | 30 | $25,078 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $20,950 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $20,042 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $18,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $996 | $243,274191 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $8,774 | $241,559305 claims |
| PfizerEliquis | $518 | $117,063108 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $48 | $78,431101 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $64 | $70,61257 claims |
| MerckJanuvia | $31 | $59,67251 claims |
| Johnson & JohnsonXarelto | $46 | $50,65941 claims |
| Lilly USA, LLCMounjaro | $124 | $44,28539 claims |
| AmgenProlia | $83 | $35,17820 claims |
| AbbVieLinzess | $253 | $25,07830 claims |
| Sanofi-aventis U.S. LLCLantus | $37 | $6,77925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Granite City
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.